ArticleLung India : official organ of Indian Chest Society2026
An international collaborative initiative to screen primary ciliary dyskinesia with high-speed video microscopy and nasal nitric oxide at a tertiary referral centre in South India.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methodological considerations on 'an international collaborative initiative to screen primary ciliary dyskinesia with high-speed video microscopy and nasal nitric oxide at a tertiary referral centre in South India'.Lung India : official organ of Indian Chest Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveTo screen patients with suspected primary ciliary dyskinesia (PCD) using high-speed video microscopy analysis (HSVA) and/or nasal nitric oxide (nNO) through an international collaborative initiative between GKNM Hospital, Coimbatore, India, and the PCD Centre, University Hospital Southampton, UK.
methodsChildren and adults up to 30 years of age with clinical features suggestive of PCD were recruited. HSVA was performed on nasal brushing biopsies for all participants. Nasal NO was measured, when feasible, in patients aged ≥5 years using a portable electrochemical NIOX VERO® device. Online multidisciplinary team meetings involving both centres reviewed and interpreted the results. Patients who tested positive on at least one of the two screening tests were classified as PCD screen-positive. Due to resource constraints, only a subset of screen-positive patients underwent genetic testing.
resultsAmong the 113 patients screened, 68 (60.1%) were PCD screen-positive. Next-generation sequencing was performed in 26 of these 68 patients, and PCD was genetically confirmed in 14 cases. The median age at diagnosis was 8.5 years.
conclusionIn resource-limited settings, diagnosis of PCD is often delayed. A combined screening strategy using HSVA and nasal NO testing can help identify likely PCD cases and facilitate early intervention. HSVA and nNO testing were found to be complementary in the screening of PCD. Genetic testing was used in a subset of patients to confirm diagnosis and was conclusive in 54% of tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.